4D Molecular Therapeutics, Inc.·4

Dec 13, 4:05 PM ET

Kirn David 4

4 · 4D Molecular Therapeutics, Inc. · Filed Dec 13, 2023

Insider Transaction Report

Form 4
Period: 2023-12-11
Kirn David
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-12-11+590,000590,000 total
    Exercise: $14.42Exp: 2033-12-10Common Stock (590,000 underlying)
Footnotes (1)
  • [F1]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4